Omalizumab Retreatment and Step-Up in Patients with Chronic Spontaneous Urticaria: OPTIMA Trial

Treatment response to omalizumab in patients with refractory chronic spontaneous urticaria

Int J Dermatol.

Syrigos N, Grapsa D, Zande M, Tziotou M, Syrigou E

doi: 10.1111/ijd.13935.

Further Publications DermatologyFurther Publications ImmunologyFurther Publications Rheumatology

Benefits and Harms of Omalizumab Treatment in Adolescent and Adult Patients With Chronic Idiopathic (Spontaneous) Urticaria: A Meta-analysis of "Real-world" Evidence

JAMA Dermatol.

Tharp MD, Bernstein JA, Kavati A, Ortiz B, MacDonald K, Denhaerynck K, Abraham I, Lee CS

doi: 10.1001/jamadermatol.

Further Publications Immunology

Safety and effectiveness of omalizumab for the treatment of chronic urticaria in pediatric patients

Pediatr Allergy Immunol

Dekkers C, Alizadeh Aghdam M, Graaf M, Knulst AC, Meijer Y, van den Reek JMPA, Stadermann MB, Röckmann H

doi: 10.1111/pai.13426

Further Publications Dermatology

Response of Peripheral Blood Basophils in Subjects with Chronic Spontaneous Urticaria During Treatment with Omalizumab

J Allergy Clin Immunol

MacGlashan D Jr, Saini S, Schroeder JT

doi: 10.1016/j.jaci.2021.02.039

Further Publications DermatologyFurther Publications ImmunologyFurther Publications Rheumatology

Canakinumab Lacks Efficacy in Treating Adult Patients with Moderate to Severe Chronic Spontaneous Urticaria in a Phase II Randomized Double-blind Placebo-controlled Single Centre Study

J Allergy Clin Immunol Pract.

Maul JT, Distler M, Kolios A, Maul LV, Guillet C, Graf N, Imhof L, Lang C, Navarini AA, Schmid-Grendelmeier P

doi: 10.1016/j.jaip.2020.07.058.

Further Publications Dermatology

Evaluation of Pharmacologic Treatments for H1 Antihistamine-Refractory Chronic Spontaneous Urticaria: A Systematic Review and Network Meta-analysis

JAMA Dermatol

Nochaiwong S, Chuamanochan M, Ruengorn C, Awiphan R, Tovanabutra N, Chiewchanvit S

doi: 10.1001/jamadermatol.2021.3237

RECOMMENDED

Autoimmune Disease

Biomarkers and clinical characteristics of autoimmune chronic spontaneous urticaria (aiCSU): Results of the PURIST Study

Allergy.

Schoepke N, Asero R, Ellrich A, Ferrer M, Gimenez-Arnau A, Grattan CEH, Jakob T, Konstantinou GN, Raap U, Skov PS, Staubach P, Kromminga A, Zhang K, Bindslev-Jensen C, Daschner A, Kinaciyan T, Knol EF, Makris M, Marrouche N, Schmid-Grendelmeier P, Sussman G, Toubi E, Church MK, Maurer M

doi: 10.1111/all.13949.

Psoriasis

Certolizumab Pegol for the Treatment of Patients with Moderate-to-Severe Chronic Plaque Psoriasis: Pooled Analysis of Week 16 Data from 3 Randomized Controlled Trials

J Eur Acad Dermatol Venereol.

Blauvelt A, Reich K, Lebwohl M, Burge D, Arendt C, Peterson L, Drew J, Rolleri R, Gottlieb AB

doi: 10.1111/jdv.15258.

Psoriasis

Benefit-risk of tofacitinib in patients with moderate to severe chronic plaque psoriasis: Pooled analysis across 6 clinical trials

Br J Dermatol.

Strober BE, Gottlieb AB, van de Kerkhof PCM, Puig L, Bachelez H, Chouela E, Imafuku S, Thaçi D, Tan H, Valdez H, Gupta P, Kaur M, Frajzyngier V, Wolk R

doi: 10.1111/bjd.17149.

Related content